Oculis Holding AG(OCS)Earnings, Financials & Key Ratios
OCS•NASDAQ
$31.09
$1.8B mkt cap·Price updated May 7, 2026
AboutOculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Show more
- Revenue$686K
- EBITDA-$73M+9.5%
- Net Income-$86M+3.4%
- EPS (Diluted)-2.12+28.6%
- Gross Margin-7492.27%
- EBITDA Margin-10611.95%
- Operating Margin-10671.14%
- Net Margin-12503.94%
- ROE-102.66%-8.4%
- ROIC-106.75%+45.9%
- Debt/Equity0.02+149.1%
OCS Key Insights
Oculis Holding AG (OCS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 35.1% in last year
- ✗Expensive at 13.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OCS Price & Volume
Oculis Holding AG (OCS) stock price & volume — 10-year historical chart
Loading chart...
OCS Growth Metrics
Oculis Holding AG (OCS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-49.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-23.73%
Return on Capital
10 Years-88.82%
5 Years-88.82%
3 Years-100.52%
Last Year-85.43%
OCS Recent Earnings
Oculis Holding AG (OCS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (18%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
Mar 3, 2026EPS
$0.51
Est $0.48
-6.7%
Revenue
$518,435
Est $142,917
+262.8%
Q4 2025
Nov 10, 2025EPS
$0.40
Est $0.50
+20.0%
Revenue
$305,460
Est $136,870
+123.2%
Q3 2025
Aug 21, 2025EPS
$0.59
Est $0.53
-11.3%
Revenue
$328,476
Est $143,340
+129.2%
Q2 2025
May 8, 2025EPS
$0.77
Est $0.51
-51.0%
Revenue
$321,944
Est $217,540
+48.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $0.51vs $0.48-6.7% | $518,435vs $142,917+262.8% |
| Q4 2025 | Nov 10, 2025 | $0.40vs $0.50+20.0% | $305,460vs $136,870+123.2% |
| Q3 2025 | Aug 21, 2025 | $0.59vs $0.53-11.3% | $328,476vs $143,340+129.2% |
| Q2 2025 | May 8, 2025 | $0.77vs $0.51-51.0% | $321,944vs $217,540+48.0% |
Based on last 12 quarters of dataView full earnings history →
OCS Peer Comparison
Oculis Holding AG (OCS) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 KALA | 617.68K | 0.08 | -0.01 | -141.11% | -388.29% | 2.62 | ||
 LENZ | 277.88M | 9.72 | -3.41 | -430.25% | -37.47% | 0.00 | ||
 NUVL | 7.53B | 102.40 | -17.50 | -42.78% | ||||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 REPL | 265.97M | 3.34 | -1.09 | -149.55% | 0.18 | |||
 AEYE | 100.43M | 8.09 | -32.36 | 14.52% | -7.63% | -47.8% | 0.15 |
Compare OCS vs Peers
Oculis Holding AG (OCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCS Income Statement
Oculis Holding AG (OCS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 686K | 504K |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 52.08M | 14.91M |
| COGS % of Revenue | - | - | - | - | 7592.27% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -51.4M▲ 0% | -14.4M▲ 0% |
| Gross Margin % | - | - | - | - | -7492.27% | -2858.13% |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 12.34M | 13.23M | 32.38M | 80.71M | 21.81M | 63.89M |
| OpEx % of Revenue | - | - | - | - | 3178.86% | - |
| Selling, General & Admin | 3.52M | 4.1M | 6.74M | 14.72M | 21.81M | 21.78M |
| SG&A % of Revenue | - | - | - | - | 3178.86% | - |
| Research & Development | 9.34M | 9.57M | 22.22M | 29.25M | 52.08M | 55.56M |
| R&D % of Revenue | - | - | - | - | 7592.27% | - |
| Other Operating Expenses | -516K | -433K | 3.41M | 36.74M | -52.08M | -228K |
| Operating Income | -12.34M▲ 0% | -13.23M▼ 7.3% | -32.38M▼ 144.7% | -80.71M▼ 149.3% | -73.2M▲ 9.3% | -78.3M▲ 0% |
| Operating Margin % | - | - | - | - | -10671.14% | -15535.32% |
| Operating Income Growth % | - | -7.26% | -144.68% | -149.3% | 9.3% | - |
| EBITDA | -12.11M | -13M | -32.08M | -80.43M | -72.8M | -77.79M |
| EBITDA Margin % | - | - | - | - | -10611.95% | -15434.13% |
| EBITDA Growth % | - | -7.34% | -146.8% | -150.73% | 9.49% | -14.78% |
| D&A (Non-Cash Add-back) | 228K | 235K | 299K | 287K | 406K | 510K |
| EBIT | -12.34M | -13.4M | -32.2M | -87.38M | -73.2M | -103.46M |
| Net Interest Income | -2.62M | -5.1M | -6.32M | 126.86K | 1.53M | 1.05M |
| Interest Income | 10K | 21K | 126K | 1.59M | 1.53M | 1.93M |
| Interest Expense | 2.63M | 5.12M | 6.44M | 1.46M | 0 | 878.43K |
| Other Income/Expense | -2.45M | -5.29M | -6.27M | -7.98M | -12.73M | -26.04M |
| Pretax Income | -14.79M▲ 0% | -18.52M▼ 25.2% | -38.64M▼ 108.6% | -88.69M▼ 129.5% | -85.94M▲ 3.1% | -104.34M▲ 0% |
| Pretax Margin % | - | - | - | - | -12527.26% | -20702.38% |
| Income Tax | 83K | 27K | 55K | 107K | -160K | -242K |
| Effective Tax Rate % | -0.56% | -0.15% | -0.14% | -0.12% | 0.19% | 0.23% |
| Net Income | -14.87M▲ 0% | -18.55M▼ 24.7% | -38.7M▼ 108.6% | -88.8M▼ 129.5% | -85.78M▲ 3.4% | -104.1M▲ 0% |
| Net Margin % | - | - | - | - | -12503.94% | -20654.37% |
| Net Income Growth % | - | -24.74% | -108.59% | -129.47% | 3.41% | -49.52% |
| Net Income (Continuing) | -14.87M | -18.55M | -38.7M | -88.8M | -85.78M | -104.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.45▲ 0% | -0.57▼ 26.7% | -1.18▼ 107.0% | -2.97▼ 151.7% | -2.12▲ 28.6% | -1.98▲ 0% |
| EPS Growth % | - | -26.67% | -107.02% | -151.69% | 28.62% | -23.73% |
| EPS (Basic) | -0.45 | -0.57 | -1.18 | -2.97 | -2.12 | - |
| Diluted Shares Outstanding | 32.73M | 32.73M | 32.73M | 29.9M | 40.41M | 52.67M |
| Basic Shares Outstanding | 32.73M | 32.73M | 32.73M | 29.9M | 40.41M | 52.67M |
| Dividend Payout Ratio | - | - | - | - | - | - |
OCS Balance Sheet
Oculis Holding AG (OCS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 6.16M | 47.98M | 23.66M | 101.02M | 104.9M | 150.91M |
| Cash & Short-Term Investments | 4.95M | 46.28M | 19.79M | 91.65M | 98.66M | 46.44M |
| Cash Only | 4.95M | 46.28M | 19.79M | 38.33M | 27.71M | 46.44M |
| Short-Term Investments | 0 | 0 | 0 | 53.32M | 70.95M | 0 |
| Accounts Receivable | 1.14M | 0 | 0 | 7.95M | 777K | 0 |
| Days Sales Outstanding | - | - | - | - | 413.42 | 604.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 1K | 911K | 1.08M | 0 | 0 | 104.47M |
| Total Non-Current Assets | 10.22M | 10.06M | 13.4M | 13.34M | 15.46M | 16.93M |
| Property, Plant & Equipment | 1.44M | 1.29M | 1.12M | 1.04M | 1.69M | 3.1M |
| Fixed Asset Turnover | - | - | - | - | 0.41x | 0.25x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 8.72M | 8.72M | 12.21M | 12.21M | 13.29M | 13.29M |
| Long-Term Investments | 50K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 52K | 74K | 89K | 476K | 2.05M |
| Total Assets | 16.38M▲ 0% | 58.04M▲ 254.3% | 37.06M▼ 36.2% | 114.35M▲ 208.6% | 120.35M▲ 5.2% | 167.84M▲ 0% |
| Asset Turnover | - | - | - | - | 0.01x | 0.00x |
| Asset Growth % | - | 254.29% | -36.15% | 208.56% | 5.25% | 176.61% |
| Total Current Liabilities | 4.34M | 4.06M | 12.02M | 19.09M | 44.23M | 33.73M |
| Accounts Payable | 790K | 824K | 3.87M | 7.6M | 5.87M | 1.22M |
| Days Payables Outstanding | - | - | - | - | 41.14 | 77.41 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 3.37M | 0 | 0 | 5.95M | 0 | 0 |
| Other Current Liabilities | -1K | 0 | 1 | -497K | 19.85M | 12.14M |
| Current Ratio | 1.42x | 11.81x | 1.97x | 5.29x | 2.37x | 2.37x |
| Quick Ratio | 1.42x | 11.81x | 1.97x | 5.29x | 2.37x | 2.37x |
| Cash Conversion Cycle | - | - | - | - | - | 527.31 |
| Total Non-Current Liabilities | 55.7M | 114.94M | 123.03M | 1.54M | 2.73M | 3.52M |
| Long-Term Debt | 53.98M | 113.5M | 122.45M | 0 | 0 | 0 |
| Capital Lease Obligations | 645K | 577K | 491K | 431K | 865K | 4.43M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.07M | 857K | 91K | 1.11M | 1.87M | 5.89M |
| Total Liabilities | 60.04M | 119M | 135.05M | 20.63M | 46.97M | 37.24M |
| Total Debt | 54.81M | 114.27M | 123.08M | 605K | 1.18M | 2.47M |
| Net Debt | 49.86M | 68M | 103.3M | -37.72M | -26.53M | -43.97M |
| Debt / Equity | - | - | - | 0.01x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | 0.57x |
| Interest Coverage | -4.69x | -2.58x | -5.03x | -55.16x | - | -117.78x |
| Total Equity | -43.65M▲ 0% | -60.95M▼ 39.6% | -97.99M▼ 60.8% | 93.73M▲ 195.6% | 73.38M▼ 21.7% | 130.59M▲ 0% |
| Equity Growth % | - | -39.63% | -60.76% | 195.65% | -21.71% | 148.03% |
| Book Value per Share | -1.33 | -1.86 | -2.99 | 3.13 | 1.82 | 2.48 |
| Total Shareholders' Equity | -43.65M | -60.95M | -97.99M | 93.73M | 73.38M | 130.59M |
| Common Stock | 297K | 335K | 39K | 366K | 446K | 559K |
| Retained Earnings | -53.73M | -72.28M | -110.98M | -199.78M | -285.56M | -361M |
| Treasury Stock | -100K | -100K | -1K | 0 | -10K | -35K |
| Accumulated OCI | -1.37M | 656K | 2.21M | -1.4M | -2.5M | 24.21M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
OCS Cash Flow Statement
Oculis Holding AG (OCS) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -12.03M | -13.82M | -25.07M | -53.84M | -47.5M | -47.5M |
| Operating CF Margin % | - | - | - | - | -6924.05% | - |
| Operating CF Growth % | - | -14.93% | -81.37% | -114.74% | 11.79% | -74% |
| Net Income | -14.79M | -18.52M | -38.64M | -88.69M | -85.94M | -104.1M |
| Depreciation & Amortization | 228K | 235K | 299K | 287K | 406K | 510K |
| Stock-Based Compensation | 328K | 328K | 804K | 3.61M | 9.78M | 10.01M |
| Deferred Taxes | 47K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.61M | 4.93M | 6.47M | 43.95M | 14.09M | 30.4M |
| Working Capital Changes | -451K | -791K | 6M | -12.99M | 14.16M | 3.45M |
| Change in Receivables | 10K | 233K | -152K | 36K | 247K | 638K |
| Change in Inventory | -10K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -649K | 30K | 3.04M | 3.73M | -1.71M | 821K |
| Cash from Investing | -19K | -28K | -3.55M | -54.21M | -17.56M | -29.43M |
| Capital Expenditures | -19K | -28K | -65K | -48K | -230K | -320K |
| CapEx % of Revenue | - | - | - | - | 33.53% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -3.48M | 0 | 0 | -2.98M |
| Cash from Financing | 4.86M | 55.19M | 1.71M | 129.67M | 54.03M | 105.43M |
| Debt Issued (Net) | -98K | -98K | -159K | -158K | -274K | -357K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 996K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -4K |
| Other Financing | -68K | -804K | -157K | -5.79M | 763K | 15.57M |
| Net Change in Cash | -7.2M▲ 0% | 41.33M▲ 674.0% | -26.49M▼ 164.1% | 18.54M▲ 170.0% | -10.62M▼ 157.3% | 10.81M▲ 0% |
| Free Cash Flow | -12.05M▲ 0% | -13.85M▼ 15.0% | -28.62M▼ 106.6% | -53.89M▼ 88.3% | -47.73M▲ 11.4% | -61.39M▲ 0% |
| FCF Margin % | - | - | - | - | -6957.58% | -12180.16% |
| FCF Growth % | - | -14.98% | -106.61% | -88.29% | 11.44% | -20.7% |
| FCF per Share | -0.37 | -0.42 | -0.87 | -1.80 | -1.18 | -1.18 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.75x | 0.65x | 0.61x | 0.55x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
OCS Key Ratios
Oculis Holding AG (OCS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -94.74% | -102.66% | -81.69% |
| Return on Invested Capital (ROIC) | -149.85% | -393.39% | -197.47% | -106.75% | -106.75% |
| Gross Margin | - | - | - | -7492.27% | -2858.13% |
| Net Margin | - | - | - | -12503.94% | -20654.37% |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.02x |
| Interest Coverage | -2.58x | -5.03x | -55.16x | - | -117.78x |
| FCF Conversion | 0.75x | 0.65x | 0.61x | 0.55x | 0.59x |
OCS Frequently Asked Questions
Oculis Holding AG (OCS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oculis Holding AG (OCS) reported $0.5M in revenue for fiscal year 2024.
Oculis Holding AG (OCS) grew revenue by 0.0% over the past year. Growth has been modest.
Oculis Holding AG (OCS) reported a net loss of $104.1M for fiscal year 2024.
Dividend & Returns
Oculis Holding AG (OCS) has a return on equity (ROE) of -102.7%. Negative ROE indicates the company is unprofitable.
Oculis Holding AG (OCS) had negative free cash flow of $61.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More OCS
Oculis Holding AG (OCS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates